Moderna, Inc.
MRNA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001682852
In the last 90 days, Moderna, Inc. insiders filed 0 open-market purchases and 4 sales; 790 institutions reported holding it in 13F filings for Q2 2026, worth $22.4B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $101.5B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $33.9M in total
- 4
- 13F holdersQ2 2026, +65 vs. previous quarter
- 790
- 13F valueReported value at the end of Q2 2026
- $22.4B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.94B
- −39.9% year over year
- Net income, FY2025
- -$2.82B
- No comparable prior period
- Free cash flow, FY2025
- -$2.06B
- No comparable prior period
- Revenue, Q3 FY2026
- $1.31B
- +29.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $2.82B (145.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 33.2M
- Shares sold short
- Change
- +587.9K
- +1.8% vs. previous
- Days to cover
- 1.76
- At average daily volume
Superinvestors holding MRNA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding MRNA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Moderna, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2026 (view filing)4:09 PM ET | Oct 14-15 | 2 days | Hoge StephenPresident | SSale | −78.4K | $217.10 | −$17.0M | −4.6%1.64M after | 3 lots10b5-1 |
| Sep 16, 2026 (view filing)4:48 PM ET | Sep 14-15 | 2 days | Hoge StephenPresident | SSale | −80.6K | $145.10 | −$11.7M | −4.9%1.56M after | 2 lots10b5-1 |
| Sep 14, 2026 (view filing)4:25 PM ET | Sep 10 | 4 days | Mock James MChief Financial Officer | SSale | −34.8K | $134.49 | −$4.69M | −37.0%59.4K after | 2 lots10b5-1 |
| Sep 3, 2026 (view filing)4:56 PM ET | Sep 1 | 2 days | Klinger Shannon ThymeChief Legal Officer | SSale | −3.47K | $139.95 | −$485.8K | −4.5%74.1K after | 10b5-1 |
| Aug 7, 2026 (view filing)4:11 PM ET | Aug 5 | 2 days | Bancel StephaneChief Executive Officer | SSale | −499.2K | $57.52 | −$28.7M | −7.5%6.19M after | 4 lots10b5-1 |
| Jul 16, 2026 (view filing)4:45 PM ET | Jul 15 | 1 day | Hoge StephenPresident | SSale | −53.3K | $67.60 | −$3.61M | −3.5%1.48M after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Hoge StephenPresident | SSale | −53.3K | $51.37 | −$2.74M | −3.5%1.48M after | 10b5-1 |
| Jun 8, 2026 (view filing) | Jun 4 | 4 days | Klinger Shannon ThymeChief Legal Officer | SSale | −3.47K | $50.00 | −$173.6K | −4.9%67.5K after | 10b5-1 |
| May 22, 2026 (view filing) | May 21 | 1 day | Afeyan NoubarDirector | SSale | −9.26K | $46.84 | −$433.9K | −70.2%3.92K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Hoge StephenPresident | SSale | −53.3K | $48.40 | −$2.58M | −3.5%1.48M after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 790 holdersThe largest institutional positions in Moderna, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 51,859,891 | $3.63B | 0.16% | +6,187,867+13.5% | Added |
| BlackRock, Inc. | 30,599,409 | $2.14B | 0.03% | +963,533+3.3% | Added |
| Vanguard Capital Management LLC | 23,208,792 | $1.63B | 0.03% | +336,334+1.5% | Added |
| Capital World Investors | 22,276,996 | $1.56B | 0.18% | +3,579,302+19.1% | Added |
| Baillie Gifford & Co | 18,206,778 | $1.28B | 1.16% | −1,779,098−8.9% | Reduced |
| State Street Corp | 15,726,193 | $1.10B | 0.03% | +864,784+5.8% | Added |
| Vanguard Portfolio Management LLC | 15,581,313 | $1.09B | 0.05% | −35,054−0.2% | Reduced |
| Geode Capital Management, LLC | 9,710,335 | $678.8M | 0.04% | +275,203+2.9% | Added |
| Morgan Stanley | 9,538,094 | $668.0M | 0.04% | +1,066,831+12.6% | Added |
| Theleme Partners LLP | 8,057,571 | $564.3M | 33.52% | +9,326+0.1% | Added |
Holders of 5% or more of MRNA
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Moderna, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 14.80%58.9M shares | +1.70 ppfrom 13.10% | May 12, 20256 filings | Nov 5, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 6.53%25.9M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
| Capital World Investors | 13G | 5.60%22.3M shares | New | Aug 12, 20261 filing | Aug 12, 2026 | SEC |
Politician trades
All politician trades in MRNA6 members of Congress reported 24 trades in Moderna, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Oct 7, 2026 |  Maria Elvira Salazar House · FL | Sell (partial) | $1K-$15K |
| Sep 9, 2026 | Maria Elvira Salazar House · FL | Sell (partial) | $1K-$15K |
| Sep 9, 2026 | Maria Elvira Salazar House · FL | Buy | $1K-$15K |
| May 8, 2025 |  Robert P. Bresnahan, Jr. House · PA | Sell | $1K-$15K |
| Mar 27, 2025 | Robert P. Bresnahan, Jr. House · PA | Buy | $1K-$15K |
House · FL · Oct 7, 2026
Sell (partial)$1K-$15K
House · FL · Sep 9, 2026
Sell (partial)$1K-$15K
House · FL · Sep 9, 2026
Buy$1K-$15K
House · PA · May 8, 2025
Sell$1K-$15K
House · PA · Mar 27, 2025
Buy$1K-$15K